Acalabrutinib is a medication used to treat certain types of cancer, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [1]. The typical dosage is 100 mg twice daily [1].
How does acalabrutinib work?
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor [1]. BTK is a protein involved in the signaling pathways of B cells, a type of white blood cell. By inhibiting BTK, acalabrutinib disrupts the growth and survival of cancerous B cells [2].
What are the approved uses for acalabrutinib?
Acalabrutinib is approved for the treatment of adult patients with CLL or SLL who have received at least one prior therapy [1]. It is also approved for adult patients with CLL or SLL regardless of prior therapy [3].
What are common side effects of acalabrutinib?
Common side effects reported with acalabrutinib include diarrhea, fatigue, headache, muscle pain, and bruising [1]. More serious side effects can occur, such as infections, bleeding, and heart rhythm problems [1]. Patients should discuss any potential risks and side effects with their healthcare provider [1].
When does acalabrutinib's patent protection end?
Information regarding the patent expiry for acalabrutinib can be found on DrugPatentWatch.com [4]. Patent expirations are crucial for understanding when generic versions of a drug may become available.
What is the difference between acalabrutinib and ibrutinib?
Both acalabrutinib and ibrutinib are BTK inhibitors used to treat similar B-cell malignancies. However, they differ in their chemical structure and binding affinity to BTK. This can lead to differences in their efficacy, side effect profiles, and potential for drug interactions [5]. Acalabrutinib is considered a second-generation BTK inhibitor designed to offer improved selectivity and potentially fewer off-target side effects compared to ibrutinib [5].
Who manufactures acalabrutinib?
Acalabrutinib is manufactured by AstraZeneca [1].
What are the clinical trial results for acalabrutinib?
Clinical trials have demonstrated the efficacy of acalabrutinib in patients with CLL and SLL. Studies have shown high response rates and improved progression-free survival compared to existing treatments [6][7]. For example, the ELEVATE-RR study showed acalabrutinib met its primary endpoint of non-inferiority in progression-free survival compared to ibrutinib in previously treated CLL patients [7].
What is the cost of acalabrutinib?
The cost of acalabrutinib can vary significantly based on insurance coverage, pharmacy, and location [8]. Patients may have access to patient assistance programs offered by the manufacturer to help with the cost [8].
Are there any alternatives to acalabrutinib for CLL/SLL?
Yes, several alternative treatments are available for CLL and SLL, including other BTK inhibitors (e.g., ibrutinib, zanubrutinib), BCL-2 inhibitors (e.g., venetoclax), and chemotherapy regimens [9]. The choice of treatment depends on factors such as the patient's disease stage, prior treatments, and overall health [9].
Sources:
[1] https://www.drugpatentwatch.com/acalabrutinib
[2] https://www.drugpatentwatch.com/blog/brutons-tyrosine-kinase-btk-inhibitors-in-cancer-treatment
[3] https://www.drugpatentwatch.com/blog/acalabrutinib-for-cll-and-sll-a-comprehensive-overview
[4] https://www.drugpatentwatch.com
[5] https://www.drugpatentwatch.com/blog/acalabrutinib-vs-ibrutinib-understanding-the-differences
[6] https://www.drugpatentwatch.com/blog/acalabrutinib-clinical-trial-results-and-patient-outcomes
[7] https://www.drugpatentwatch.com/blog/elevate-rr-acalabrutinib-vs-ibrutinib-in-cll
[8] https://www.drugpatentwatch.com/blog/acalabrutinib-cost-and-insurance-coverage
[9] https://www.drugpatentwatch.com/blog/alternative-treatments-for-cll-and-sll